Tags

Type your tag names separated by a space and hit enter

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Am J Geriatr Psychiatry. 2006 Aug; 14(8):704-15.AJ

Abstract

OBJECTIVE

The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease (AD).

METHOD

This was a randomized, double-blind, placebo-controlled clinical trial conducted at 42 U.S. sites. Participants were 403 outpatients with mild to moderate AD and Mini-Mental State Examination scores of 10-22 randomized to memantine (20 mg/day; N=201) or placebo (N=202) for 24 weeks. Primary outcomes were change from baseline at 24 weeks on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), a measure of cognition, and on the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), a global measure. Secondary outcomes included change on the Neuropsychiatric Inventory (NPI) and the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL(23)), measures of behavior and function, respectively.

RESULTS

Most (82.4%) participants completed the trial. Memantine resulted in significantly better outcomes than placebo on measures of cognition, global status, and behavior when based on the protocol-specified primary last observation carried forward imputation as well as a mixed-models repeated-measures approach applied to the continuous outcomes. Treatment discontinuations because of adverse events for memantine versus placebo were 19 (9.5%) and 10 (5.0%), respectively.

CONCLUSIONS

These results support the safety and efficacy of memantine for the treatment of mild to moderate AD.

Authors+Show Affiliations

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine and Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Seattle, WA 98108, USA. peskind@u.washington.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16861375

Citation

Peskind, Elaine R., et al. "Memantine Treatment in Mild to Moderate Alzheimer Disease: a 24-week Randomized, Controlled Trial." The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry, vol. 14, no. 8, 2006, pp. 704-15.
Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704-15.
Peskind, E. R., Potkin, S. G., Pomara, N., Ott, B. R., Graham, S. M., Olin, J. T., & McDonald, S. (2006). Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry, 14(8), 704-15.
Peskind ER, et al. Memantine Treatment in Mild to Moderate Alzheimer Disease: a 24-week Randomized, Controlled Trial. Am J Geriatr Psychiatry. 2006;14(8):704-15. PubMed PMID: 16861375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. AU - Peskind,Elaine R, AU - Potkin,Steven G, AU - Pomara,Nunzio, AU - Ott,Brian R, AU - Graham,Stephen M, AU - Olin,Jason T, AU - McDonald,Scott, PY - 2006/7/25/pubmed PY - 2006/10/14/medline PY - 2006/7/25/entrez SP - 704 EP - 15 JF - The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry JO - Am J Geriatr Psychiatry VL - 14 IS - 8 N2 - OBJECTIVE: The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease (AD). METHOD: This was a randomized, double-blind, placebo-controlled clinical trial conducted at 42 U.S. sites. Participants were 403 outpatients with mild to moderate AD and Mini-Mental State Examination scores of 10-22 randomized to memantine (20 mg/day; N=201) or placebo (N=202) for 24 weeks. Primary outcomes were change from baseline at 24 weeks on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), a measure of cognition, and on the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), a global measure. Secondary outcomes included change on the Neuropsychiatric Inventory (NPI) and the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL(23)), measures of behavior and function, respectively. RESULTS: Most (82.4%) participants completed the trial. Memantine resulted in significantly better outcomes than placebo on measures of cognition, global status, and behavior when based on the protocol-specified primary last observation carried forward imputation as well as a mixed-models repeated-measures approach applied to the continuous outcomes. Treatment discontinuations because of adverse events for memantine versus placebo were 19 (9.5%) and 10 (5.0%), respectively. CONCLUSIONS: These results support the safety and efficacy of memantine for the treatment of mild to moderate AD. SN - 1064-7481 UR - https://www.unboundmedicine.com/medline/citation/16861375/Memantine_treatment_in_mild_to_moderate_Alzheimer_disease:_a_24_week_randomized_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1064-7481(12)60572-7 DB - PRIME DP - Unbound Medicine ER -